Revolution Medicines Inc
Change company Symbol lookup
Select an option...
RVMD Revolution Medicines Inc
ATI Allegheny Technologies Inc
GTLS Chart Industries Inc
STC Stewart Information Services Corp
ARCH Arch Resources Inc
MSFT Microsoft Corp
FCX Freeport-McMoRan Inc
EFX Equifax Inc
CHKP Check Point Software Technologies Ltd
CTXS Citrix Systems Inc
Go

Company profile

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

Price
Delayed
$40.02
Day's Change
1.47 (3.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
40.54
Day's Low
36.51
Volume
(Light)

Today's volume of 154,641 shares is on pace to be much lighter than RVMD's 10-day average volume of 327,009 shares.

154,641
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.